Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity.

Abstract

Dramatic improvements in cancer survival have arisen because of the rapid development of novel anti-cancer therapies. The potential for cardiovascular toxicity associated with these drugs often reflects overlap between pathogenic cancer mechanisms and physiological pathways required for normal cardiovascular function. Clinical Science has, therefore, compiled a themed collection on Cardiovascular-Oncology. This collection examines the intersection between cancer treatments and their potentially harmful cardiovascular effects. By defining the mechanisms underlying unwanted cardiovascular effects of anti-cancer therapies, cardioprotective strategies can be developed. Only by doing so, will patients be able to achieve optimal cancer treatment at the minimum cost to cardiovascular health.

• Authors: Ninian N Lang, Rhian M Touyz
• Journal: Clinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 135 Issue 23 Pg. 2661-2663 (12 10 2021) ISSN: 1470-8736 [Electronic] England
• PMID: 34881389 (Publication Type: Editorial, Introductory Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Author(s).

Chemical References

• Anthracyclines
• Antineoplastic Agents

Topics

• Anthracyclines (adverse effects)
• Antineoplastic Agents (adverse effects)
• Cardiotoxicity (etiology, prevention & control)
• Humans
• Immunotherapy
• Molecular Targeted Therapy
• Neoplasms (drug therapy)